瓜蒌皮注射液联合阿托伐他汀治疗冠心病的疗效和安全性评价  

Evaluation of the efficacy and safety of Gualoupi injection combined with atorvastatin in the treatment of coronary heart disease

作　　者：黄朝发 张榕华 HUANG Chaofa;ZHANG Ronghua(Internal Medicine-Cardiovascular Department of Guangxin District People’s Hospital,Shangrao,Jiangxi 334100,China)

机构地区：[1]江西上饶市广信区人民医院心血管内科,江西334100

出　　处：《上海医药》2021年第4期18-20,共3页Shanghai Medical & Pharmaceutical Journal

摘　　要：目的:探讨瓜蒌皮注射液联合阿托伐他汀治疗冠心病的疗效和安全性。方法:选择2018年6月—2019年6月收治的120例冠心病患者,随机分为对照组和观察组各60例。对照组给予口服阿托伐他汀钙片治疗,20 mg/次,1次/d,共4周。观察组在此基础上加用瓜蒌皮注射液静脉滴注,1次/d,共4周。两组均随访6个月,比较两组疗效和安全性。结果:观察组总有效率为95.00%(57/60),高于对照组的81.67%(49/60,P<0.05)。治疗后,观察组每周心绞痛发作频率为(2.58±0.77)次,心绞痛发作持续时间每次为(2.15±0.44)min,分别低于对照组的(4.52±1.11)次和(4.71±0.97)min,组间差异有统计学意义(P<0.05)。观察组西雅图心绞痛量表(SAQ)评分为(85.06±8.79)分,高于对照组的(78.93±8.83)分(P<0.05)。两组治疗期间均未见明显药物不良反应。观察组在随访期间的心血管事件总发生率为5.00%(3/60),低于对照组的16.67%(10/60,P<0.05)。结论:瓜蒌皮注射液联合阿托伐他汀治疗冠心病疗效显著,安全性良好,值得临床推荐。Objective:To investigate the efficacy and safety of Gualoupi injection combined with atorvastatin in the treatment of coronary heart disease.Methods:One hundred and twenty patients with coronary heart disease admitted from June 2018 to June 2019 were selected and randomly divided into a control group and an observation group with 60 cases each.The control group was treated with oral atorvastatin calcium tablets,20 mg/time,once daily for 4 weeks.On this basis,the observation group was given an intravenous drip of Gualoupi injection once daily for 4 weeks.Both groups were followed up for 6 months to compare their efficacy and safety.Results:The total effective rate was 95.00%(57/60)in the observation group,which was higher than 81.67%in the control group(49/60,P<0.05);after treatment,the frequency of angina pectoris in the observation group was(2.58±0.77)times per week,and the duration of angina pectoris was(2.15±0.44)min each time,which were lower than those in the control group(4.52±1.11)and(4.71±0.97),respectively.and the difference between groups was statistically significant(P<0.05).The Seattle Angina Pectoris scale(SAQ)score in the observation group was(85.06±8.79)points,which was higher than the(78.93±8.83)points in the control group(P<0.05).There were no obvious adverse drug reactions in the two groups during treatment.The total incidence of cardiovascular events in the observation group during the follow-up period was 5.00%(3/60),which was lower than 16.67%in the control group(10/60,P<0.05).Conclusion:Gualoupi injection combined with atorvastatin has significant efficacy and good safety in the treatment of coronary heart disease,and is worthy of clinical recommendation.

关 键 词：冠心病 瓜蒌皮注射液 阿托伐他汀 疗效 安全性 

分 类 号：R541.4[医药卫生—心血管疾病]